Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

TransMedics Group (TMDX) Stock Price & Analysis

1,907 Followers

TMDX Stock Chart & Stats

$91.38-$0.62(-0.67%)
At close: 4:00 PM EST
$70$80$90Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$91.17 - $94.28
52-Week Range
$60.11 - $156.00
Previous Close
$92.00
Volume
N/A
Average Volume (3M)
1.12M
Market Cap
$3.20B
Enterprise Value
$3.78B
Total Cash (Recent Filing)
$492.96M
Total Debt (Recent Filing)
$866.90M
Price to Earnings (P/E)
21.8
Beta
0.72
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
0.45
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Rapid multi-year revenue expansion and 41% quarterly growth indicate strong adoption of the OCS ecosystem and related services. Continued case-volume growth can deepen customer utilization, expand the installed platform base, and support durable operating scale over the next several quarters.

Recurring Case-based Business Model

The combination of recurring consumables and case-based logistics services links revenue to transplant activity and customer utilization rather than only upfront device sales. This model can improve revenue visibility and create repeat purchasing as OCS penetration and procedure volumes increase.

Large Clinical Growth Pipeline

The heart and lung programs could materially expand the addressable market beyond current indications, while approved study protocols provide a defined path to generate clinical evidence. Successful execution could support broader adoption, international expansion, and additional recurring case revenue.

Bears Say

Higher Leverage

The sharp increase in debt relative to equity reduces financial flexibility and raises fixed obligations as the company continues investing in expansion. If margins remain under pressure, higher leverage could constrain capital allocation and make execution more sensitive to operating setbacks.

Weakening Cash Conversion

Positive operating cash flow is offset by weaker conversion of accounting earnings into cash and a substantial decline in free cash flow. This suggests working-capital needs or capital spending are absorbing profits, limiting internally funded investment and reducing balance-sheet resilience.

Margin Compression And Investment Burden

Operating leverage has weakened as strategic investment and expanding expenses outpace profitability, while service mix and PAD Aviation pressure gross margin. Although these investments may support growth, sustained cost intensity could delay margin recovery and reduce earnings durability.

TransMedics Group News

TMDX FAQ

What was TransMedics Group’s price range in the past 12 months?
TransMedics Group lowest stock price was $60.11 and its highest was $156.00 in the past 12 months.
What is TransMedics Group’s market cap?
TransMedics Group’s market cap is $3.20B.
When is TransMedics Group’s upcoming earnings report date?
TransMedics Group’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 107 days.
How were TransMedics Group’s earnings last quarter?
TransMedics Group released its earnings results on Nov 05, 2026. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.298 by $0.212.
Is TransMedics Group overvalued?
According to Wall Street analysts TransMedics Group’s price is currently Undervalued.
Does TransMedics Group pay dividends?
TransMedics Group does not currently pay dividends.
What is TransMedics Group’s EPS estimate?
TransMedics Group’s EPS estimate is 0.45.
How many shares outstanding does TransMedics Group have?
TransMedics Group has 34,733,883 shares outstanding.
What happened to TransMedics Group’s price movement after its last earnings report?
TransMedics Group reported an EPS of $0.51 in its last earnings report, beating expectations of $0.298. Following the earnings report the stock price went up 27.921%.
Which hedge fund is a major shareholder of TransMedics Group?
Hedge funds hold TransMedics Group shares: the largest hedge-fund position in TransMedics Group is 71,886,833 shares, and hedge funds decreased their holdings by 15.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology